Folinic Acid: Mechanism in Oncology and Antidote

Folinic acid (internationally Leucovorin, chemically 5-formyltetrahydrofolate, trade names Calciumfolinate and generics) is the active folate form that can enter folate metabolism directly, bypassing dihydrofolate reductase. In medicine, folinic acid has three central applications: as an antidote in methotrexate high-dose therapy (rescue therapy), as an enhancer of fluorouracil efficacy in gastrointestinal oncology, and as substitution for folate deficiency.

Unlike simple folic acid, folinic acid does not need to be activated via dihydrofolate reductase. This property makes it indispensable in patients receiving methotrexate, because methotrexate inhibits precisely this enzyme. Simple folic acid administration would be ineffective in this setting. In gastrointestinal oncology, folinic acid potentiates the antitumoral effect of fluorouracil by stabilizing the ternary complex between 5-FdUMP and thymidylate synthase.

Mechanism of Action

Folinic acid is converted intracellularly to reduced folate derivatives, which serve as cofactors in the synthesis of purines, thymidine, and several amino acids. Unlike folic acid, it does not require the first reduction step via dihydrofolate reductase, which is blocked by methotrexate. Thus, folinic acid can restore folate metabolism even during ongoing methotrexate therapy and reduce cellular toxicity in normal cells.

When combined with fluorouracil, 5-FdUMP, the active metabolite of fluorouracil, forms a ternary complex with thymidylate synthase. Folinic acid as methylenetetrahydrofolate stabilizes this complex and thereby enhances inhibition of thymidine synthesis in tumor cells. This synergy is the basis of modern gastrointestinal chemotherapy regimens such as FOLFOX and FOLFIRI.

Pharmacokinetically, folinic acid shows good oral bioavailability after oral administration (approximately 90 percent at doses below 25 mg). At higher doses, bioavailability decreases, which is why parenteral administration is often chosen in oncology. The half-life is approximately 5 to 7 hours. Metabolism occurs predominantly hepatic and renal to inactive metabolites.

Indications

• Methotrexate rescue therapy, following high-dose methotrexate in oncology (for example, in leukemia, lymphoma, osteosarcoma)
• Antidote for methotrexate overdose or accidental administration of high doses
• Enhancement of fluorouracil efficacy in regimens such as FOLFOX, FOLFIRI, FOLFIRINOX for colorectal, gastric, pancreatic, or esophageal carcinoma
• Substitution for folate deficiency with megaloblastic anemia, especially when folic acid is insufficient due to metabolic peculiarities
• Adjunctive use in pyrimethamine therapy (for example, toxoplasmosis prophylaxis or treatment), to reduce hematologic toxicity
• Adjunctive use in trimethoprim-sulfamethoxazole high-dose therapy for Pneumocystis pneumonia

Folinic acid is not intended for routine substitution in simple folate deficiency, where folic acid is often sufficient as a more economical alternative. Self-medication is not available for oncologic indications.

Dosage and Administration

Methotrexate rescue: Begin 24 hours after methotrexate infusion, 15 mg every 6 hours for at least 60 hours, continued individually based on methotrexate levels and clinical tolerance.

Methotrexate overdose: Initial 15 mg per square meter intravenously every 3 hours, adjusted based on methotrexate serum levels and clinical presentation.

With fluorouracil in oncology: 200 mg per square meter intravenously before fluorouracil or as bolus or continuous infusion according to regimen.

Pyrimethamine adjunctive therapy: 5 to 10 mg daily orally, to reduce hematologic side effects.

Folate deficiency: 5 to 15 mg daily orally.

Renal insufficiency: Caution and adjustment according to level monitoring in methotrexate rescue therapy. Hepatic insufficiency: Generally no dose adjustment required.

Administration: Oral tablets with water, parenteral administration in specialized settings.

Side Effects

Common: Nausea, vomiting, mild allergic skin reactions.

Occasional: Sleep disturbances, irritability, headaches.

Rare: Severe allergic reactions including anaphylaxis, especially with intravenous administration.

In combination with fluorouracil: Folinic acid enhances the antitumoral effect and thus also the toxicity of fluorouracil. Mucositis, diarrhea, and bone marrow suppression occur more frequently and more severely than with fluorouracil alone. Clinical monitoring and possible dose reduction are necessary.

In methotrexate rescue: Efficacy depends on correct timing. Delayed or insufficient folinic acid administration after high-dose methotrexate can lead to severe bone marrow suppression, mucositis, hepatotoxicity, and renal insufficiency.

Drug Interactions

• Methotrexate: Intended antagonism in rescue therapy. When methotrexate is administered intrathecally, folinic acid MUST NOT be given intrathecally because it abolishes the therapeutic effect.
• Fluorouracil: Synergistic effect desired in oncologic regimens.
• Pyrimethamine: Complementary adjunctive use to reduce hematologic toxicity in toxoplasmosis therapy.
• Trimethoprim-sulfamethoxazole: Folinic acid reduces hematologic toxicity in high-dose therapy.
• Antiepileptic drugs (phenytoin, phenobarbital, primidone): High folate doses can reduce antiepileptic drug levels and trigger seizures. Individual adjustment required in patients with epilepsy.
• Capecitabine: Fluorouracil prodrug, similar interaction as with fluorouracil directly.

Special Precautions

Pregnancy: Use possible with clear indication, for example methotrexate rescue in acute leukemia in the mother. Breast-feeding: Transfer into breast milk in small amounts, individual assessment.

Children: Established in pediatric oncology, dosage adjusted by weight.

Important in methotrexate rescue: Folinic acid must be given at the exact correct time. Premature administration can reduce methotrexate efficacy on the tumor, delayed or insufficient administration leads to severe toxicity. A standardized regimen with methotrexate level monitoring is mandatory.

Never intrathecal: Folinic acid MUST NOT be given intrathecally when methotrexate is administered intrathecally because it abolishes the therapeutic effect. For intrathecal methotrexate overdose, folinic acid is administered systemically.

Before starting therapy: Check medical history and concomitant medications, especially methotrexate or fluorouracil-based regimens, prepare level measurements if necessary.

Lifestyle: In patients receiving pyrimethamine or trimethoprim-sulfamethoxazole therapy, folinic acid administration can significantly improve tolerability. Consultation with the treating specialist (oncologist, infectious disease specialist, hematologist) is advisable.

Driving ability: Generally not impaired by folinic acid itself.

You might also be interested in

• Methotrexate, antimetabolite cytostatic with folinic acid rescue
• Fluorouracil, pyrimidine analog with folinic acid enhancement
• Cisplatin, platinum compound in combination regimens
• Oxaliplatin, platinum compound in gastrointestinal oncology
• Azathioprine, another antimetabolite

Frequently Asked Questions

Sources

• Gelbe Liste, Calciumfolinate Drug Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Oncology Guidelines
• ESMO, European Society for Medical Oncology